Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.310
-0.020 (-0.86%)
At close: Sep 11, 2026, 4:00 PM EDT
2.450
+0.140 (6.06%)
After-hours: Sep 11, 2026, 7:59 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$40,317
Profits / Employee
-$782,584
Market Cap
276.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| ProQR Therapeutics | 187 |
| Sutro Biopharma | 128 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Immuneering | 57 |
| Pyxis Oncology | 56 |
| Camp4 Therapeutics | 48 |
FATE News
- 4 days ago - Fate Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 days ago - Fate Therapeutics announces clinical data from FT819 study - TheFly
- 4 days ago - Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting - GlobeNewsWire
- 10 days ago - Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Fate Therapeutics reports Q2 EPS (25c), consensus (26c) - TheFly
- 4 weeks ago - Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo - TheFly
- 4 weeks ago - Fate Therapeutics intiates first patient in RECLAIM-LN trial - TheFly
- 4 weeks ago - Fate Therapeutics price target raised to $8 from $6 at Piper Sandler - TheFly